Previous 10 | Next 10 |
Investigating unexpected findings from Phase 2b study of seladelpar in NASH In parallel, board and management evaluating all potential strategic alternatives to maximize shareholder value and implementing cost containment efforts Conference call and webcast today at 4:30 p...
Today, we will see why Intercept Pharmaceuticals (ICPT) can be an attractive albeit high-risk pick in 2020. Company overview Intercept Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies targeting progressive non-v...
Navistar International NAV +55% with Volkswagen finally making move for acquisition . More news on: Lianluo Smart Limited, Aduro BioTech, Inc., OpGen, Inc., Stocks on the move, , Read more ...
NEWARK, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the publication of a Letter to Shareholders. ...
Stealth BioTherapeutics (NASDAQ: MITO ) -56% after elamipretide flunks late-stage PMM study. More news on: Stealth BioTherapeutics Corp, Valeritas Holdings, Inc., Abeona Therapeutics Inc., Stocks on the move, Read more ...
Aimed at cutting operating expenses, CymaBay Therapeutics (NASDAQ: CBAY ) will terminate 60% of its employees , along with other measures, as it explores strategic alternatives. The majority of the layoffs will happen this month. The company will record a charge of $3-4M, mostly this quarte...
But Will This Attention Translate Into A Big Win For These Penny Stocks? Investing in penny stocks is often regarded as one of the best ways of generating substantial returns within a relatively short span of time. Moreover, an investor does not even need to invest a lot of money to buy pen...
Wall Street had a good session on Monday, celebrating a more optimistic view on trade and general economic prospects. Major merger and acquisition activity was also a highlight of the day. Yet some stocks ended up getting left out of the party and saw their shares sink precipitously. Aurora Can...
Shares of CymaBay Therapeutics (NASDAQ: CBAY) fell over 76% today after the company announced that it was halting the development of its lead drug candidate, seladelpar, in primary biliary cholangitis (PBC). The company also announced that it had decided to terminate the development of the d...
Gainers: JanOne (NASDAQ: JAN ) +103% . More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Peck Company Holdings, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...